{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:09:09Z","timestamp":1791425349539,"version":"4.3.3"},"reference-count":75,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>T- and B-cell subtypes of prolymphocytic leukemia (PLL) are rare, aggressive lymphoid malignancies with characteristic morphologic, immunophenotypic, cytogenetic, and molecular features. Recent studies have highlighted the role of specific oncogenes, such as TCL-1, MTCP-1, and ATM in the case of T-cell and TP53 mutations in the case of B-cell prolymphocytic leukemia. Despite the advances in the understanding of the biology of these conditions, the prognosis for these patients remains poor with short survival and no curative therapy. The advent of monoclonal antibodies has improved treatment options. Currently, the best treatment for T-PLL is intravenous alemtuzumab, which has resulted in very high response rates of more than 90% when given as first-line treatment and a significant improvement in survival. Consolidation of remissions with autologous or allogeneic stem cell transplantation further prolongs survival, and the latter may offer potential cure. In B-PLL, rituximab-based combination chemo-immunotherapy is effective in fitter patients. TP53 abnormalities are common and, as for chronic lymphocytic leukemia, these patients should be managed using an alemtuzumab-based therapy. The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored further in both T- and B-cell PLL to broaden the patient eligibility for what may be a curative treatment.<\/jats:p>","DOI":"10.1182\/blood-2012-01-380139","type":"journal-article","created":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T06:09:07Z","timestamp":1338444547000},"page":"538-551","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":158,"title":["How I treat prolymphocytic leukemia"],"prefix":"10.1182","volume":"120","author":[{"given":"Claire","family":"Dearden","sequence":"first","affiliation":[{"name":"Department of Haemato-Oncology, Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111809033807300_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2141.1974.tb06769.x","article-title":"Prolymphocytic leukaemia.","volume":"27","author":"Galton","year":"1974","journal-title":"Br J Haematol"},{"issue":"7823","key":"2019111809033807300_B2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(73)93135-8","article-title":"Prolymphocytic leukaemia of B and T cell type.","volume":"2","author":"Catovsky","year":"1973","journal-title":"Lancet"},{"key":"2019111809033807300_B3","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"2","key":"2019111809033807300_B4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.1998.00977.x","article-title":"Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia: Groupe Francais d'Hematologie Cellulaire.","volume":"103","author":"Garand","year":"1998","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111809033807300_B5","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia.","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"key":"2019111809033807300_B6","first-page":"525","article-title":"Prolymphocytic leukaemia of B- and T-cell types.","volume-title":"Chronic Lymphoid Leukaemias","author":"Matutes","year":"2001"},{"issue":"8","key":"2019111809033807300_B7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.leu.2400725","article-title":"The human T-cell lymphotropic viruses type 1\/11 are not involved in T Prolymphocytic leukaemia and large granular lymphocytic leukaemia.","volume":"11","author":"Pawson","year":"1997","journal-title":"Leukemia"},{"issue":"1","key":"2019111809033807300_B8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.1986.tb07579.x","article-title":"The morphological spectrum of T-prolymphocytic leukaemia.","volume":"64","author":"Matutes","year":"1986","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111809033807300_B9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.1987.tb02352.x","article-title":"Alpha, beta and gamma T-cell receptor genes: rearrangements correlate with haematological phenotype in T cell leukaemias.","volume":"67","author":"Foroni","year":"1987","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111809033807300_B10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD 52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"issue":"2","key":"2019111809033807300_B11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/jcp.49.2.154","article-title":"Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis.","volume":"49","author":"Matutes","year":"1996","journal-title":"J Clin Pathol"},{"issue":"4","key":"2019111809033807300_B12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood.V70.4.926.926","article-title":"Cytogenetic studies on prolymphocytic leukaemia: II. T cell prolymphocytic leukemia.","volume":"70","author":"Brito-Babapulle","year":"1987","journal-title":"Blood"},{"issue":"24","key":"2019111809033807300_B13","first-page":"5452","article-title":"TCL1 is overexpressed in patients affected by adult T-cell Leukemias.","volume":"57","author":"Narducci","year":"1997","journal-title":"Cancer Res"},{"issue":"9","key":"2019111809033807300_B14","first-page":"2475","article-title":"MTCP-1: a novel gene on the human chromosome Xq28 translocated on the T cell receptor alpha\/delta locus in mature T cell proliferations.","volume":"8","author":"Stern","year":"1993","journal-title":"Oncogene"},{"issue":"2","key":"2019111809033807300_B15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0165-4608(97)00410-X","article-title":"Abnormalities of chromosomes 8,11,14 and X in T-prolymphocytic leukaemia studied by fluorescence in situ hybridization.","volume":"103","author":"Maljaei","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"2019111809033807300_B16","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/sj.leu.2401034","article-title":"Abnormalities of the short arm of chromosome 12 in T cell prolymphocytic leukaemia.","volume":"12","author":"Salomon-Nguyen","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"2019111809033807300_B17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/gcc.1141","article-title":"A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia.","volume":"31","author":"Soulier","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2019111809033807300_B18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","article-title":"High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.","volume":"111","author":"Herling","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111809033807300_B19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of CAMPATH-1H antibody on human haematopoietic progenitors in vitro.","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"issue":"7","key":"2019111809033807300_B20","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","article-title":"Treatment of T-cell prolymphocytic leukaemia with human CD52 antibody.","volume":"15","author":"Pawson","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111809033807300_B21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"22","key":"2019111809033807300_B22","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111809033807300_B23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111809033807300_B24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3324\/haematol.2010.033159","article-title":"Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.","volume":"96","author":"Montagna","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"2019111809033807300_B25","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of Pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111809033807300_B26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bmt.1701127","article-title":"Treatment of T prolymphocytic leukaemia with allogeneic bone marrow transplantation.","volume":"21","author":"Collins","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111809033807300_B27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1034\/j.1600-0609.2001.00377.x","article-title":"Treatment of T-prolymphocytic leukaemia with nonmyeloablative allogeneic stem cell transplantation.","volume":"66","author":"Gardaret","year":"2001","journal-title":"Eur J Haematol"},{"issue":"7","key":"2019111809033807300_B28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.bmt.1705294","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in a patient with T-cell prolymphocytic leukaemia: graft versus tumour effect and long-term remission.","volume":"37","author":"de Lavallade","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111809033807300_B29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbmt.2009.11.021","article-title":"Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.","volume":"16","author":"Kalaycio","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111809033807300_B30","first-page":"S75","article-title":"T-prolymphocytic leukemia (T-PLL) is sensitive to graft-versus-leukemia effects: evidence from minimal residual disease (MRD) kinetics [abstract].","volume":"94","author":"Rieger","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2019111809033807300_B31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2141.2010.08134.x","article-title":"Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.","volume":"149","author":"Krishnan","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111809033807300_B32","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/leu.2011.304","article-title":"Hematopoietic stem cell transplantation in T-cell prolymphocytic leukemia (T-PLL): a retrospective study from the European Group for Blood and Marrow Transplantation (EBMT) and the Royal Marsden Consortium.","volume":"26","author":"Wiktor-Jedrzejczak","year":"2012","journal-title":"Leukemia"},{"key":"2019111809033807300_B33","article-title":"Sequential therapy of fludarabine, mitoxantrone and cyclophosphamide (FMC) induction followed by alemtuzumab consolidation is effective and safe in patients with T-cell prolymphocytic leukemia (T-PLL): results from a multicentre phase II trial of the German CLL study group (GCLLSG) [abstract].","volume":"22","author":"Hopfinger","year":"2011","journal-title":"Ann Oncol"},{"issue":"32","key":"2019111809033807300_B34","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111809033807300_B35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","article-title":"Campath-1H treatment of T-cell prolymphocytic leukaemia in patients for whom at least one prior chemotherapy regimen has failed.","volume":"20","author":"Keating","year":"2002","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111809033807300_B36","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/10428190127515","article-title":"Immunophenotyping changes and loss of CD 52 expression in two patients with relapsed T cell prolymphocytic leukaemia.","volume":"42","author":"Tuset","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111809033807300_B37","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.2007.14.1986","article-title":"Phase I trial of nelarabine in indolent leukemia.","volume":"26","author":"Gandhi","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111809033807300_B38","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1182\/blood.V91.10.3920","article-title":"Inactivation of the ATM gene in T-cell prolymphocytic leukaemia.","volume":"91","author":"Stoppa-Lyonnet","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2019111809033807300_B39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ng0997-96","article-title":"Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.","volume":"17","author":"Vorechovsk\u00fd","year":"1997","journal-title":"Nat Genet"},{"issue":"2","key":"2019111809033807300_B40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood.V87.2.423.bloodjournal872423","article-title":"Leukemia and lymphoma in ataxia telangiectasia.","volume":"87","author":"Taylor","year":"1996","journal-title":"Blood"},{"issue":"22","key":"2019111809033807300_B41","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2019111809033807300_B42","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1182\/blood-2006-11-059501","article-title":"The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKC theta and ERK pathways.","volume":"110","author":"Despouy","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111809033807300_B43","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/sj.leu.2404968","article-title":"Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia.","volume":"21","author":"R\u00f6th","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"2019111809033807300_B44","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/sj.leu.2404877","article-title":"Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q23).","volume":"21","author":"D\u00fcrig","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111809033807300_B45","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2007-06-095570","article-title":"Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia.","volume":"111","author":"Le Toriellec","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111809033807300_B46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cancergencyto.2009.03.001","article-title":"Recurrent loss, but lack of mutations, of the SMARCB1 tumour suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition.","volume":"192","author":"Bug","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2019111809033807300_B47","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2141.1986.tb05563.x","article-title":"The relationship between chronic lymphatic leukaemia and prolymphocytic leukaemia: I. Clinical and laboratory features of 300 patients and characterization of an intermediate group.","volume":"63","author":"Melo","year":"1986","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111809033807300_B48","first-page":"1640","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.","volume":"8","author":"Matutes","year":"1994","journal-title":"Leukemia"},{"issue":"7","key":"2019111809033807300_B49","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/sj.leu.2404238","article-title":"IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukaemia (B-PLL).","volume":"20","author":"Del Giudice","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2019111809033807300_B50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0165-4608(83)90084-5","article-title":"Chromosome abnormalities in B-cell prolymphocytic leukemia: a study of nine cases.","volume":"9","author":"Pittman","year":"1983","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"2019111809033807300_B51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2401644","article-title":"Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia.","volume":"14","author":"Lens","year":"2000","journal-title":"Leukemia"},{"issue":"1","key":"2019111809033807300_B52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0165-4608(97)00358-0","article-title":"Cytogenetic abnormalities in three patients with B-cell prolymphocytic leukemia.","volume":"103","author":"Sol\u00e9","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2019111809033807300_B53","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cancergencyto.2003.09.009","article-title":"Translocations (8;14)(q24;q32) as the sole cytogenetic abnormality in B-cell prolymphocytic leukaemia.","volume":"150","author":"Kuriakose","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"2019111809033807300_B54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2004.04913.x","article-title":"B-Prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia.","volume":"125","author":"Ruchlemer","year":"2004","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111809033807300_B55","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"2019111809033807300_B56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.2009.140","article-title":"Nuclear expression of SOX11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms.","volume":"23","author":"Chen","year":"2010","journal-title":"Mod Pathol"},{"issue":"6","key":"2019111809033807300_B57","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood.V89.6.2015","article-title":"p53 abnormalities in B-cell prolymphocytic leukaemia.","volume":"89","author":"Lens","year":"1997","journal-title":"Blood"},{"issue":"11","key":"2019111809033807300_B58","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2009.137","article-title":"B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.","volume":"23","author":"Del Giudice","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111809033807300_B59","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5858\/2003-127-0305-MBCLWM","article-title":"Mature B-cell leukemias with more than 55% prolymphocytes: report of 2 cases with Burkitt lymphoma-type chromosomal translocations involving c-myc.","volume":"127","author":"Merchant","year":"2003","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2019111809033807300_B60","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.leukres.2006.06.010","article-title":"Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia.","volume":"31","author":"Crisostomo","year":"2007","journal-title":"Leuk Res"},{"issue":"4","key":"2019111809033807300_B61","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2007-07-098848","article-title":"Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity.","volume":"111","author":"Traverse-Glehen","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111809033807300_B62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428199909093739","article-title":"B-cell prolymphocytic leukaemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course.","volume":"33","author":"Shivdel","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111809033807300_B63","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.1979.tb01159.x","article-title":"Complete remission in prolymphocytic leukaemia with the combination chemotherapy CHOP.","volume":"42","author":"Sibbald","year":"1979","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111809033807300_B64","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0609.1997.tb01409.x","article-title":"2-chlorodeoxyadenosine in the treatment of relapsed\/refractory chronic lymphoproliferative disorders.","volume":"58","author":"Rondelli","year":"1997","journal-title":"Eur J Haematol"},{"issue":"1","key":"2019111809033807300_B65","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.1997.15.1.37","article-title":"Majority activity of cladribine in patients with de novo B cell prolymphocytic leukaemia.","volume":"15","author":"Saven","year":"1997","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111809033807300_B66","article-title":"Fludarabine\/cyclophosphamide chemotherapy for B-prolymphocytic leukaemia [abstract].","volume":"102","author":"Herold","year":"2003","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"1","key":"2019111809033807300_B67","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cncr.11000","article-title":"Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.","volume":"97","author":"Montillo","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"2019111809033807300_B68","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00277-003-0805-z","article-title":"Successful treatment of B-cell prolymphocytic leukemia with monocloncal anti-CD20 antibody.","volume":"83","author":"Mourad","year":"2004","journal-title":"Ann Hematol"},{"issue":"1","key":"2019111809033807300_B69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00277-008-0541-5","article-title":"A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.","volume":"88","author":"Tempescul","year":"2009","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111809033807300_B70","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2011.01680.x","article-title":"Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.","volume":"87","author":"Chow","year":"2011","journal-title":"Eur J Haematol"},{"issue":"12","key":"2019111809033807300_B71","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","article-title":"Bendamustine\/mitoxantrone\/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.","volume":"45","author":"Weide","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111809033807300_B72","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ajh.20843","article-title":"Complete response to alemtuzumab in a patient with B prolymphocytic leukaemia.","volume":"82","author":"Chaar","year":"2007","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111809033807300_B73","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x","article-title":"Subcutaneous CAMPATH-1H in fludarabine-resistant\/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.","volume":"96","author":"Bowen","year":"1997","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111809033807300_B74","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1365-2141.1981.tb02755.x","article-title":"Splenic irradiation in B-prolymphocytic leukaemia.","volume":"48","author":"Oscier","year":"1981","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111809033807300_B75","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/sj.bmt.1704991","article-title":"Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: long term follow-up.","volume":"35","author":"Castagna","year":"2005","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/3\/538\/1362291\/zh802912000538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/3\/538\/1362291\/zh802912000538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T13:54:39Z","timestamp":1642341279000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/3\/538\/30480\/How-I-treat-prolymphocytic-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,19]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-01-380139","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,19]]}}}